SI
SI
discoversearch

Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
116 46 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
116>> Though still good, aren't some other players in the DLBCL space alsscaram(o)uche-23 minutes ago
115Trillium has proposed that, once the handcuffs are off, macrophages/monocytes cascaram(o)uche-44 minutes ago
114Good thoughts. It's been a while since I looked closely at the stuff (like tuck-1 PM
113car-Ts.... significant expense, antigen-negative relapse. ADCs.... relapsescaram(o)uche11 PM
112Responses down a bit from last update. Though still good, aren't some othertuck-12 PM
111s2.q4cdn.com s2.q4cdn.com Looks good. Looks very good.scaram(o)uche-11 AM
110Well if they can get a clear win in some indication (not just some singles), theBiomaven-last Wednesday
109Well, they need to increase data-set, so they have more leverage in negotiation!Miljenko Zuanic-last Monday
108Seems clear since Nov. 15th that nothing is in the works for partnering if they semi_infinite -last Monday
107So, here we are.... December. Business Development is concerned with editing scaram(o)uche-last Monday
106My personal hematologist thinks that TTI-2341 is the real gem of the pipeline. Bladerunner17-November 27
105Nan Guo Ring a Institute for Stem Cell Biology and Regenerative Medicine, and Lscaram(o)uche-November 24
104New paper from Weissman/47; full text might have more info on epitope? Anti-SIRtuck-November 24
103Poster gives me more clarity on cytokine response than the abstract that only gasemi_infinite -November 12
102I posted some TRIL SITC observations starting here: twitter.comBiomaven-November 12
101Found some background data on cytokines for comparison with Tril data released isemi_infinite -November 8
100To my uneducated eye, the abstracts for ASH look pretty interesting, especially Bladerunner17-November 7
99Peter had commented in valuation thread that "If you take a stock like Trisemi_infinite -November 7
98TRIL hits another 52-week high at $10.10. $10 may hold today. BladerunnerBladerunner17-November 7
97TRIL hits new 52-week high. ($10) It has pulled back some. BladerunnerBladerunner17-November 6
96<At the same time, there is no need for the company to rush business developmMiljenko Zuanic-November 6
95The bull case for TRIL from "Seeking Alpha" The CD47 Space Is HeatinBladerunner17-November 5
94ASH abstracts now available, and TRIL has 2. 1/6 OR in DLBCL for monotherapy, btuck-November 1
93Good size round B, Forty Seven Inc...... markets.businessinsider.com (pointer scaram(o)uche-October 17
92TRIL analysis from "Seeking Alpha" seekingalpha.com Summary SharesBladerunner17-October 15
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.